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Abstract
Purpose: Alveolar osteitis (AO) is the most common postoperative complication of dental extractions. The pur-
pose of this study was to compare the effectiveness of 1% versus 0.2% chlorhexidine (CHX) gel in reducing post-
operative AO after surgical extraction of mandibular third molars, and assess the impact of treatment on the Oral 
HealthRelated Quality of Life (OHRQoL).
Material and Methods: This clinical study was a randomized, double-blind clinical trial. Eighty eight patients 
underwent surgical extraction of one retained mandibular third molar with the intra-alveolar application of 0.2% 
CHX gel. Afterwards, they were assigned to one of two groups: 1% CHX gel (n=42) or 0.2% CHX gel (n=46). The 
patients applied the gel twice a day to the wound for one week. All patients were evaluated for AO.
Results: In the 0.2% CHX gel group, 13% of AO incidence was found, while in the 1% CHX gel group, AO inci-
dence was 7%, a difference that was not statistically significant. Variables such as sensation of pain and inflamma-
tion at baseline and during one week, as well as OHRQoL of the patients at 24 hours and 7 days post-extraction, 
gave no statistically significant differences.
Conclusions: There are no significant differences in AO after surgical extraction of mandibular third molars, when 
comparing applying 1% CHX gel twice a day for 7 days with 0.2% CHX gel. 
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Introduction
Alveolar osteitis (AO) is the most common postopera-
tive complication of dental extractions (1), affecting the 
Oral Health Related Quality of Life (OHRQoL) of pa-
tients (2). It may also be referred to as alveolitis sicca 
dolorosa, fibrinolytic alveolitis, or localized osteitis; 
and Crawford was the first to use the term “dry socket” 
in 1896. Recently, Blum (3) has suggested the following 
definition for dry socket: postoperative pain surround-
ing the alveolus that increases in severity for some peri-
od from 1 to 3 days after extraction, followed by partial 
or total clot loss in the interior of the alveolus, with or 
without halitosis.
The frequency of AO for all dental extractions ranges 
from 3% to 4% according to various authors (3). How-
ever, the highest incidence, from 5% to 30% (4) of cas-
es, generally occurs following the extraction of retained 
mandibular third molars. 
The exact etiology of AO has not yet been defined. Two 
basic theories prevail, involving   fibrinolytics (5) and 
bacterial infection (6), while epidemiological studies 
have identified several risk factors, such as difficulty 
of extraction, the surgeon’s inexperience, use of oral 
contraceptives, advanced age, female gender, smoking, 
immunosuppression, poor oral hygiene, and surgical 
trauma (7). Accordingly, prevention is held to be the 
best option (8). Several drugs have been used topically 
in the prevention of AO, among them antifibrinolytic 
agents, although antiseptics and antibiotics have proven 
more successful in prevention to date (4). 
The most commonly used antiseptic is chlorhexidine 
(CHX). A meta-analysis (9) provides clinically sig-
nificant evidence that a protocol of CHX mouth rinses, 
beginning on the same day of third molar removal and 
followed for seven days after extraction, reduces the in-
cidence of AO. A recent review shows that 0.2% CHX 
gel, applied in the alveolus site twice a day for 7 days 
post-extraction, may be the best preventive measure 
(10) because it does not interfere with the local alveolar 
hemostasis (11).
CHX has been shown to exert greater immediate in vivo 
antibacterial effect and substantivity than other anti-
septics used in the oral cavity (12). The substantivity 
of CHX is influenced by different factors, among them 
the concentration (13). Bioadhesive gels with higher 
concentrations of CHX have shown greater effective-
ness in various clinical situations: periodontal treatment 
(14), after oral surgery procedures (15), implant dentist-
ry (16), plaque control (17), caries prevention (18), and 
oral wound healing (19). Therefore, the objective of our 
study was to compare the effectiveness of week-long 
applications of CHX gel, in concentrations of 0.2% and 
1%, in preventing postoperative AO after the extraction 
of retained mandibular third molars, as well as their im-
pact on the patients OHRQoL.
Material and Methods
This clinical study was a randomized, clinical trial with 
two parallel groups, following the Consort statement 
(20). The study involved the treatment of 88 patients 
of both genders, 18 to 44 years of age, between Janu-
ary 2009 and January 2011 at the School of Dentistry 
of the University of Granada, and the Oral and Maxil-
lofacial Surgery Service of Virgen de las Nieves Hospi-
tal of Granada (Spain). These patients presented almost 
one retained mandibular third molar with a difficulty 
index ranging from 4 through 7 (both included) accord-
ing to the Koerner scale (21). The degree of difficulty 
was rated by two pre-calibrated surgeons who also per-
formed the surgery. Exclusion criteria were: taking an-
tibiotics or analgesics in the four days before the proce-
dure, other disease contraindicating oral surgery, AIDS 
or immunosuppression, pregnancy or lactation in the 
women, allergy to CHX, articaine, paracetamol or ibu-
profen, epinephrine contraindication, the simultaneous 
extraction of two third molars, any jawbone-associated 
pathology, and uncooperative patients (psychic-motor 
dysfunction and behavior disorders), or those for whom 
the extraction took over 30 minutes.
All of the patients in the study gave their written in-
formed consent. The study was approved by the Ethics 
Committees of the University of Granada and the Vir-
gen de las Nieves Hospital of Granada, and followed the 
principles of the Helsinki Declaration.
Two pharmaceutical forms of digluconate CHX gel 
were studied: 0.2% (Laboratorios KIN S.A., Barcelona, 
Spain) and 1% (GlaxoSmithline Consumer Healthcare, 
Dublin, Ireland).
Before the surgical treatment, the surgeons registered 
several variables at the base level, and taught the pa-
tients to measure them over a week. Using a millimetric 
ruler, maximum interincisal aperture (basal, and days 1, 
2 and 7), and edema (basal, days 1, 2, 3, 4, 5 and 7) were 
measured. To determine the latter, the following points 
were marked: mandibular angle, tragus, lateral canthus, 
base of nasal wing, labial commisure, and pogonion of 
the side to be operated. From the mandibular angle to 
each one of the other points, measurements were made 
using the ruler. Also noted were the sensation of pain 
(basal, 3 and 7 hours and daily) and inflammation (ba-
sal, 3 and 7 hours, and days 1, 2 and 7) on an analogical 
visual scale of 0 to 100. 
The patients underwent the procedure under local an-
esthesia (articaine 40mgr/ml- epinephrine 0. 01%; Lab-
oratorios Normon S.A., Madrid, Spain) applied to the 
inferior alveolar, long buccal and lingual nerves. An 
enveloped or triangular flap was performed in order to 
gain access to the third molar, carrying out osteotomy 
and dental sectioning when necessary. Once the tooth 
had been extracted, the alveolus was cleaned, the bone 
edges were smoothed, folicular remnants and granula-
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tion tissue were eliminated, and bioadhesive 0.2% chlo-
rhexidine gel was applied inside the alveolus. Finally, 
the wound was sutured with simple 4/0 silk stitches.
The patients were randomly classified into two groups, 
0.2% CHX gel (n= 46) or 1% CHX gel (n=42), by means 
of a simple allocation using a computer program. All 
patients were instructed to adhere to topical treatment 
beginning on the day of intervention and for seven days 
thereafter using one of the two bioadhesive CHX gels. 
They were asked to brush their teeth twice a day, us-
ing a soft surgical toothbrush, and then apply the corre-
sponding CHX gel on the surgical wound. As postopera-
tive symptomatic treatment, all the patients took 600 mg 
of ibuprofen every 8 hours and 1 gr paracetamol every 
12 hours. 
As the main variable we took the appearance (or not) 
of post-operatory alveolitis during one week, following 
the diagnostic criteria put forth by Blum (3). Telephone 
calls were made for follow-up. If the patient complained 
of pain, an appointment was set for clinical evaluation. 
The tolerance to treatment was also assessed, reported 
by the patient using a visual analogical scale of 1 to 5, 
along with repercussion on the OHRQoL of the patient 
on days 1 and 7 after surgery. To this end, we used a 
questionnaire designed by Savin and Ogden (22) con-
sisting of 16 items and five dimensions.
Sample size was estimated following the general rule 
linked to the standardized difference in a given output 
variable between the two groups. The estimation was 
based on detection of a standardized difference of 0.6, 
which is between moderate (0.5) and large (0.8). This 
gives a size of 40 patients per group for a power of 75% 
(β=0.25) and a significance level of α=0.05. Data analy-
sis was carried out using SPSS Windows 15.0 (SPSS 
Inc., Chicago, IL). The descriptive and analytical meth-
ods applied are indicated in the table and figure. 
Results
A total of 88 patients underwent intervention (88 man-
dibular third molars). All 46 patients in the 0.2% CHX 
gel group and 42 patients in the 1% CHX gel group 
completed the study. The mean age was 26 (range 18 to 
44). Forty-six patients were female and 42 were male. 
Twenty-two patients were smokers, and nine women 
were taking oral contraceptives. 
The risk factors of both groups with regard to sociode-
mographic variables, clinical variables, and the surgical 
procedure are shown in table 1. No significant statistical 
Table 1. Description and comparison of patients (n=88).
MRP-surgeon 1, DSL-surgeon 2. MV=mesio-vestibular, MVD=mesio-vestibular-distal, MVDO=mesio-
vestibular-distal-occlusal.
a: Percent distribution rounded to integers for clarity. b: n=24 and n=22 in 0.2%- and 1%-groups, respec-
tively.
c: A scale from 1 (low) to 5 (high). d: Corresponds to n=6 alveolitis, with two of them also abscess.
e: Corresponds to n=3 alveolitis, with 1 and 2, also with abscess or cellulitis, respectively.
f: Chi squared with Yates correction. g: Student t Test for independent samples.
h: Mann-Whitney test. i: Bilateral Fisher's exact test. j: chi-squared.
Variable CHX 0.2% (n=46) 
CHX 1% 
(n=42) p-value 
Sociodemographics 
 Sex (Men-Women) (%)a
 Age (14 to 24, 25-44) (%) 
 Age (mean±sd) 
 Educational level (Primary-Secondary-University) (%) 
48-52 
54-46 
25.6±6.9 
22-26-52 
48-52 
43-57 
26.8±6.1 
21-31-48 
0.846f
0.604g
0.764h
Clinical chart 
 Systemic disease (No-Yes) (%) 
 Contraceptives (only womenb) (No-Yes) (%) 
 Good oral Hygiene (Yes-No) (%) 
 Pre-pericoronaritis (No-Yes) (%) 
 Tobacco (No-?10 cig./day->10 cig./día) (%) 
96-4 
79-21 
72-28 
72-28 
76-9-15 
95-5 
82-18 
71-29 
81-19 
74-17-9 
?1i
?1i
0.838f
0.446f
0.952h
Surgical procedure 
 Molar (38-48) (%) 
 Surgeon (MRP-DSL) (%) 
 Extraction time min. (mean±sd) 
 Difficulty in extraction (mean±sd) 
 Exposure (Included-Semierupted) (%) 
 Osteotomy (No-MV-MVD-MVDO) (%) 
 Odontosection (No-Yes) (%) 
 Flap enveloped or triangular (%) 
57-43 
77-33 
12.6±6.7 
5.47±1.07 
30-70 
67-9-15-9 
85-15 
91-9 
55-45 
48-52 
10.9±5.9 
5.33±1.20 
38-62 
57-3-26-14 
74-26 
83-17 
0.961f
0.097f
0.213g
0.558g
0.595f
0.283j
0.312f
0.420f
After surgery 
 Alveolitis (No-Yes) (%) 
 Tolerance (mean±sd)h
87-13d
4.35±0.87 
93-7e
4.48±0.77 
0.488i
0.524g
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differences were found between the two groups (13% of 
AO incidence in the 0.2% gel CHX group, 7% in the 1% 
gel CHX group; (Table 1). Furthermore, the surgeon did 
not significantly (with a logistic regression model) influ-
ence the group effect (results not shown).
The baseline subjective sensation of pain, inflammation, 
and evolution over the week-long follow up, reflected in 
figure 1, shows no significant differences between the 
two groups. Figure 2 indicates the maximum interincis-
al aperture before extraction and at days 1, 2 and 7, with 
no statistically significant differences seen between the 
two groups. The baseline level and the evolution of ede-
ma are presented in figure 3, again without significant 
differences for any of the variables studied.
None of the patients displayed adverse effects to the 
treatment. The results in terms of OHRQoL of the pa-
Fig. 1. Pain and inflammation, from pre-extraction (day 0) to day 7. Continuous 
lines refer to group CHX 1%, and discontinuous lines to group CHX 0.2%. In-
flammation for days 3 to 6 are extrapolations (not collected).
Comparisons between the two groups are non-significant (p>0.05, Mann-Whit-
ney test) for all variables and for all times. All measurements within each line are 
significantly higher than basal measurements (p<0.05, Wilcoxon’s test).
Fig. 2. Maximum bucal aperture at pre-extraction (day 0), days 1, 2 and 7. Continuous lines refer to group 
CHX 1%, and discontinuous lines to group CHX 0.2%. Comparisons between the two groups are non-
significant (p>0.05, Mann-Whitney test) for all variables and for all times. All measurements within each 
line are significantly lower than basal measurements (p<0.05, Wilcoxon’s test).
Med Oral Patol Oral Cir Bucal. 2013 Jul 1;18 (4):e693-700.                                                 1% versus 0.2% chlorhexidine gels in reducing alveolar osteitis from mandibular third molar surgery
e697
tients at 24 hours and at 7 days post-extraction are given 
in table 2. No statistically significant differences could 
be established for the two groups for any of the items on 
day 1 or on day 7. A comparison of the evolution within 
each group during this week showed improvement in all 
the dimensions of the questionnaire except for “psycho-
social effects”.
Discussion
In view of the high frequency of AO after surgical ex-
tractions, and especially in retained lower third molars 
(4), and the clinical manifestations that can affect the 
OHRQoL (23), the prevention of this pathology is par-
ticularly relevant. Although the exact etiology of AO 
has not yet been defined (24), the influence of bacte-
ria appears to be important (5). A number of local and 
systemic risk factors have also been described (4) and 
should be taken into account in any research about the 
treatment or prevention of AO. 
This study is a double-blind randomized clinical trial 
(RCTs), following Consort statements (20), a gold 
standard for studying preventive and therapeutic in-
terventions. The double-blindedness was maintained 
throughout the study, and comparison of the risk factors 
derived from the patient and those of the interventions 
showed there were no significant differences between 
the two groups established. Any selection bias is there-
fore unlikely. One possible limitation to be addressed, 
however, is that our study did not include a control 
group without treatment. This decision was made when 
designing the study given the demonstrated efficacy of 
CHX in the prevention of AO (4,10).
The diagnostic criterion for AO was described by Blum 
(3) as the one most used in epidemiological studies (10), 
thus allowing for the comparison of results. The ques-
tionnaire about OHRQoL had been previously applied 
to studies of third molar surgery (22,23), and it is easy 
for patients to understand and fill out. 
Many researchers (4,9,10) have sought to prevent or re-
duce the incidence of AO. Local treatment with antibi-
otics, specifically tetracycline, is supported by strong 
evidence from available RCTs to have a clinically rel-
evant effect on prevention of AO (4), but caution should 
be taken due to potentially serious adverse effects with 
its intra-alveolar use, such as hypersensitivity reactions 
and potential for systemic toxicity (24). The use of CHX 
is associated with fewer adverse effects (25). 
With a high level of evidence, Caso et al. (9) published 
a meta-analysis of CHX. Its use intra-operatively and 
7 days postoperatively appears to reduce the frequency 
of AO following surgical removal of lower third mo-
lars, and in addition, entails no serious adverse effects. 
Fig. 3. Different facial measurements from mandibular angle, from pre-extraction (day 1) to day 7. Continuous lines refer to group 
CHX 1%, and discontinuous lines to group CHX 0.2%. Comparisons between both groups are non-significant (p>0.05, Mann-
Whitney test) for all variables and for all times. All measurements within each line are significantly higher than basal measurements 
(p<0.05, Wilcoxon’s test), except for MAB at day 7 (p=0.085).
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However, this meta-analysis only studied CHX in solu-
tion. A study evaluating the effects of CHX gel reports 
that one application of 0.2% CHX bioadhesive gel post-
extraction in the alveolus site (15) reduced the incidence 
of AO by 19% (a significant difference) with respect to 
a control group undergoing no local treatment. Taking 
into account this result, it was decided, for ethical rea-
sons, that both groups should receive 0.2% CHX bioad-
hesive gel post-extraction in the alveolus site. We used 
CHX gel applied every 12 hours for 7 days after extrac-
tion. Although this option is more expensive than CHX 
in solution, a recent systematic review including studies 
with CHX gel concludes that it is the best available op-
tion for the prevention of AO (10).
Our aim was to improve, if possible, the good results 
obtained using 0.2% CHX gel (26). The effect of CHX 
is dose-dependent. A major concentration can increase 
substantivity (13) and its bactericidal effect (27). Also, 
the properties of bioadhesive CHX gel, particularly its 
high viscosity, can reduce the clearance of the active 
agent from the place of the extractions (28). On the 
other hand, the use of 1% CHX gel has shown better 
results in different clinical situations (14-18). We there-
fore surmised that increasing 5 times the concentration 
of a bioadhesive CHX gel could further reduce AO in-
cidence. Although the incidence of AO in the 1% CHX 
gel group was nearly half that obtained for 0.2% CHX 
gel (7.1% versus 13%), the difference was not statisti-
cally significant. These results can be considered in the 
same interval as those obtained by Hita et al. (26), who 
used the same methodology, and found 7.5% of AO in 
their 0.2% gel CHX group as opposed to 25% in a group 
using 0.12% CHX mouth rinse.
A lack of differences between the two groups of our 
study was also reflected by the subjective and objective 
variables studied: evolution of pain, level of inflam-
mation, and interincisal aperture. Assessment of the 
patients´ OHRQoL one and seven days after surgery 
showed similar results for the two groups, indicating no 
substantial difference between using a 1% CHX gel or 
a 0.2% CHX gel.
Our results could be explained by the use of 0.2% CHX 
gel inside the alveolus in both groups. Because this 
procedure in itself has shown an important reduction 
of AO (19%) (15), achieving a lower incidence was a 
major challenge. It was not possible using 1% CHX gel 
inside the alveolus, as we had originally considered, due 
to possible side effects not yet studied (29). The appli-
cation of the lower concentration of CHX (0.2%) may 
result in the formation of a relatively stable monolayer 
of retained CHX in the oral mucosa, while the higher 
concentration might have given only an oversaturation 
of CHX with a rapid release of its excess (30).
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